Tikva raises $8M for off-the-shelf cancer therapy
Tikva Allocell is preparing a donor-derived T-cell programme for regulatory submission and first-in-human testing.
Personalised cell therapies can be powerful, but they are expensive and slow to manufacture. Tikva Allocell is trying to replace that patient-by-patient process with an off-the-shelf treatment.
What happened
Tikva Allocell raised an $8M Series A led by Kantharos Capital.
The financing will support IND-enabling studies and a planned regulatory submission for TAVST01, a donor-derived engineered T-cell therapy targeting B7-H3-positive solid tumours.
Subject to regulatory clearance, Tikva plans to begin a Phase 1 clinical trial in Singapore and the US. The programme remains preclinical, so safety and efficacy in patients have not yet been established.
Why it matters
Most commercially successful CAR-T therapies use a patient's own cells and are concentrated in blood cancers. Manufacturing them requires specialised collection, engineering and logistics, which can delay treatment and increase cost.
A donor-derived product could be produced in advance and supplied more like a conventional medicine. The harder scientific challenge is avoiding immune rejection while maintaining activity inside solid tumours, where cell therapies have historically struggled.
The bigger picture
The cell-therapy market is shifting toward platforms that promise broader access and simpler manufacturing. Investors are funding companies that can turn a complex personalised procedure into a repeatable product.
Tikva's round is tied to a clear milestone: reaching the clinic. The next evidence will come from whether TAVST01 can be administered safely and show early biological activity, not from the platform concept alone.